Danaher Corporation
I · Analyse IA
En bref
Danaher manufactures specialized equipment and supplies that pharmaceutical companies use to develop and produce drugs, particularly biologics like monoclonal antibodies. They also make diagnostic instruments for hospitals and research labs, along with software and consumables that support the entire drug development lifecycle. The company serves customers in over 60 countries through well-known brands like Beckman Coulter, Leica Microsystems, and Pall.
Danaher is a $118 billion healthcare and life sciences conglomerate that makes equipment, chemicals, and software used by pharmaceutical companies and hospitals [Yahoo Finance]. The company operates through three divisions: Biotechnology (equipment for drug manufacturing), Life Sciences (research instruments and genomics tools), and Diagnostics (hospital testing equipment) [Yahoo Finance]. Despite recent stock underperformance, its core bioprocessing business is recovering strongly with equipment orders up 30%+ as pharma companies expand production capacity [Yahoo Finance].
Solid cash generation with moderate leverage, though profitability metrics show room for improvement
Score Sentinellis
6.3/10
Moderate concerns
Capitalisation boursière
$118.2B
Chiffre d'affaires (12 mois)
$24.6B
II · Actualités récentes
Ce qui a fait bouger le cours
6 stories · ranked by relevance
- macro2026-05-20
Strength in Danaher's Biotechnology Unit Seems Firm: More Upside Ahead?
Yahoo Finance
- macro2026-05-20
Why The Narrative Around Danaher (DHR) Is Shifting With Bioprocess Recovery And Masimo Deal
Simply Wall St
- macro2026-05-19
Genedata Introduces AI-Native CMC Platform to Accelerate Drug Development and Manufacturing
Yahoo Finance
- macro2026-05-18
Life Science Instrumentation Market Forecast Report 2025-2031: Expanding Activities in Genomics, Proteomics, and Drug Discovery with Thermo Fisher Scientific, Danaher, Agilent, and Shimadzu Leading
Yahoo Finance
- macro2026-05-18
Japan In Vitro Diagnostics Market Research Trends and Forecast Report 2026-2035 Featuring, Abbott Laboratories, Arkray, Danaher, Fujirebio, H.U., Roche Diagnostics, Sysmex, Tosoh
Yahoo Finance
- macro2026-05-17
Solid Q1 and Guidance Underlines Why Danaher Corporation (DHR) is one of Steve Cohen’s Large-Cap Stock Picks
Yahoo Finance
Premium · gratuit avec tout compte
The stock has fallen 27% in 2026 following multiple weak quarterly earnings reports, significantly underperforming the S&P 500's 27% gain over the past year [Yahoo Finance]
Risques
5
Opportunités
7
Signaux d'alerte
3
Direction
10
24 autres constats dans le rapport complet — gratuit avec tout compte.
Débloquer l'analyse complète de Danaher Corporation
Créez un compte gratuit pour accéder au rapport complet généré par IA, avec les sources citées dans le texte.
- 5 risques, 7 opportunités et 3 signaux d'alerte — chacun avec sa source
- Plus de 100 indicateurs financiers avec graphiques et comparaisons
- Résumés d'actualités complets avec liens vers les sources
- Équipe dirigeante et rémunération
- Export PDF pour la lecture hors ligne
III · Entreprises similaires
À lire également
Same sector · Healthcare or comparable health
L'ajouter à votre liste ?